Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
MONARCH 2: Overall survival of abemaciclib plus fulvestrant in HR+, HER2- advanced breast cancer - YouTube
Lead team presentation
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis | HTML
PALOMA-3: Overall survival (OS) with palbociclib plus fulvestrant in HR+,HER2_ ABC - YouTube
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies - ScienceDirect
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Presentación de PowerPoint
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
Figure 2 from Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
The growing role of CDK 4 6 inhibitors
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. - Abstract - Europe PMC
